ES2531159T3 - Compuestos y métodos para el tratamiento del cáncer - Google Patents
Compuestos y métodos para el tratamiento del cáncer Download PDFInfo
- Publication number
- ES2531159T3 ES2531159T3 ES06824793T ES06824793T ES2531159T3 ES 2531159 T3 ES2531159 T3 ES 2531159T3 ES 06824793 T ES06824793 T ES 06824793T ES 06824793 T ES06824793 T ES 06824793T ES 2531159 T3 ES2531159 T3 ES 2531159T3
- Authority
- ES
- Spain
- Prior art keywords
- compounds
- methods
- cancer treatment
- formula
- crystalline compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 abstract 2
- 230000008018 melting Effects 0.000 abstract 1
- 238000002844 melting Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/285—Arsenic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/66—Arsenic compounds
- C07F9/70—Organo-arsenic compounds
- C07F9/72—Aliphatic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Un compuesto cristalino que tiene una estructura de fórmula (I)**Fórmula** o una de sus sales farmacéuticamente aceptables, en donde el compuesto cristalino tiene un punto de fusión en el intervalo de 180-200 ºC y en el que la cantidad de clorhidrato de piridina residual es inferior al 5 % en peso.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70416305P | 2005-07-29 | 2005-07-29 | |
PCT/US2006/029835 WO2007027344A2 (en) | 2005-07-29 | 2006-07-28 | Compounds and methods for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2531159T3 true ES2531159T3 (es) | 2015-03-11 |
Family
ID=37809342
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES06824793T Active ES2531159T3 (es) | 2005-07-29 | 2006-07-28 | Compuestos y métodos para el tratamiento del cáncer |
ES11180330.0T Active ES2532666T3 (es) | 2005-07-29 | 2006-07-28 | Compuestos y métodos para el tratamiento del cáncer |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11180330.0T Active ES2532666T3 (es) | 2005-07-29 | 2006-07-28 | Compuestos y métodos para el tratamiento del cáncer |
Country Status (9)
Country | Link |
---|---|
US (3) | US7968738B2 (es) |
EP (2) | EP1919564B1 (es) |
JP (1) | JP4994374B2 (es) |
AU (1) | AU2006285329B2 (es) |
CA (1) | CA2617049A1 (es) |
ES (2) | ES2531159T3 (es) |
HK (2) | HK1117780A1 (es) |
NO (1) | NO20081045L (es) |
WO (1) | WO2007027344A2 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1919564B1 (en) | 2005-07-29 | 2014-11-26 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
TW200829261A (en) | 2006-09-29 | 2008-07-16 | Ziopharm Oncology Inc | Method for controlling angiogenesis in animals |
KR20100100835A (ko) | 2007-11-02 | 2010-09-15 | 지오팜 온콜로지 인코포레이티드 | 유기 비소제와의 병용 요법 |
EP2231684A4 (en) * | 2007-12-12 | 2011-09-07 | Ziopharm Oncology Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER |
JP5933896B2 (ja) | 2008-08-20 | 2016-06-15 | ソレイジア・ファーマ株式会社 | 有機ヒ素化合物および癌を処置するための方法 |
WO2014045083A1 (en) | 2012-09-20 | 2014-03-27 | Bendale Yogesh Narayan | Process for bio synthesis of nano arsenic trioxide and its use in treatment of diseases including cancers |
WO2015085208A1 (en) * | 2013-12-05 | 2015-06-11 | Solasia Pharma K.K. | Compounds and methods for the treatment of cancer |
JP6793113B2 (ja) * | 2015-03-12 | 2020-12-02 | Kmバイオロジクス株式会社 | 脱細胞化組織を用いた癒着防止材及び代用生体膜 |
CN107167433A (zh) * | 2016-03-07 | 2017-09-15 | 天津国际生物医药联合研究院 | 一种检测氯二甲基砷的方法 |
JPWO2019220961A1 (ja) * | 2018-05-18 | 2020-05-28 | ソレイジア・ファーマ株式会社 | ダリナパルシンのアルカリ金属塩及び/又は無機酸付加塩の結晶型及びその製剤 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
EP1374875A3 (en) * | 1997-10-15 | 2004-01-07 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositons comprising arsenic for the treatment of myelodysplastic syndrome |
JP2001522799A (ja) | 1997-11-10 | 2001-11-20 | メモリアル スローン−ケタリング キャンサー センター | 三酸化ヒ素製剤の製造方法および三酸化ヒ素またはメラルソプロールを使用する癌の治療方法 |
JP2001525371A (ja) * | 1997-12-05 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | Glp−1製剤 |
CN1233476A (zh) * | 1998-04-24 | 1999-11-03 | 陆道培 | 治疗急性白血病的药物及其制备方法 |
SE9802080D0 (sv) * | 1998-06-11 | 1998-06-11 | Hellstroem | Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein |
EP1002537A1 (en) | 1998-10-30 | 2000-05-24 | Assistance Publique, Hopitaux De Paris | Use of melarsoprol for the manufacture of a medicament for treating B-cell lymphoproliferative diseases, such as multiple myeloma |
US6191123B1 (en) * | 1999-03-19 | 2001-02-20 | Parker Hughes Institute | Organic-arsenic compounds |
AU2001253919B2 (en) * | 2000-04-26 | 2006-12-14 | Government Of The United States, D/B/A Department Of Veterans Affairs | Administration of a thiol-based chemoprotectant compound |
JP4571408B2 (ja) * | 2002-01-07 | 2010-10-27 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 癌治療薬としての、s−ジメチルアルシノ−チオコハク酸、s−ジメチルアルシノ−2−チオ安息香酸、s−(ジメチルアルシノ)グルタチオン |
TW201350113A (zh) * | 2004-07-16 | 2013-12-16 | Texas A & M Univ Sys | 有機砷化合物、其用於治療癌症之用途及包含其之醫藥組成物 |
EP1919564B1 (en) | 2005-07-29 | 2014-11-26 | Ziopharm Oncology, Inc. | Compounds and methods for the treatment of cancer |
KR20100100835A (ko) * | 2007-11-02 | 2010-09-15 | 지오팜 온콜로지 인코포레이티드 | 유기 비소제와의 병용 요법 |
-
2006
- 2006-07-28 EP EP06824793.1A patent/EP1919564B1/en active Active
- 2006-07-28 ES ES06824793T patent/ES2531159T3/es active Active
- 2006-07-28 WO PCT/US2006/029835 patent/WO2007027344A2/en active Application Filing
- 2006-07-28 ES ES11180330.0T patent/ES2532666T3/es active Active
- 2006-07-28 CA CA002617049A patent/CA2617049A1/en not_active Abandoned
- 2006-07-28 AU AU2006285329A patent/AU2006285329B2/en not_active Ceased
- 2006-07-28 US US11/495,172 patent/US7968738B2/en active Active
- 2006-07-28 JP JP2008524273A patent/JP4994374B2/ja active Active
- 2006-07-28 EP EP11180330.0A patent/EP2394702B1/en not_active Not-in-force
-
2008
- 2008-02-28 NO NO20081045A patent/NO20081045L/no not_active Application Discontinuation
- 2008-11-07 HK HK08112236.1A patent/HK1117780A1/xx unknown
- 2008-11-07 HK HK12105772.9A patent/HK1164767A1/xx unknown
-
2011
- 2011-06-01 US US13/150,516 patent/US8334398B2/en active Active
-
2012
- 2012-11-14 US US13/676,929 patent/US8865764B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP1919564B1 (en) | 2014-11-26 |
WO2007027344A2 (en) | 2007-03-08 |
US20120022229A1 (en) | 2012-01-26 |
HK1164767A1 (en) | 2012-09-28 |
WO2007027344A3 (en) | 2007-12-21 |
US8865764B2 (en) | 2014-10-21 |
EP2394702A1 (en) | 2011-12-14 |
EP1919564A2 (en) | 2008-05-14 |
NO20081045L (no) | 2008-04-25 |
AU2006285329A2 (en) | 2008-08-14 |
US7968738B2 (en) | 2011-06-28 |
AU2006285329A1 (en) | 2007-03-08 |
AU2006285329B2 (en) | 2012-10-04 |
HK1117780A1 (en) | 2009-01-23 |
JP4994374B2 (ja) | 2012-08-08 |
ES2532666T3 (es) | 2015-03-30 |
US20130142730A1 (en) | 2013-06-06 |
US20070183972A1 (en) | 2007-08-09 |
JP2009502971A (ja) | 2009-01-29 |
US8334398B2 (en) | 2012-12-18 |
CA2617049A1 (en) | 2007-03-08 |
EP2394702B1 (en) | 2014-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2531159T3 (es) | Compuestos y métodos para el tratamiento del cáncer | |
BR112018070602A2 (pt) | composto, composição farmacêutica, uso do composto, e, método para tratar uma doença ou distúrbio | |
CL2012002526A1 (es) | Uso de compuestos inhibidores de dpp iv de formula (i) o (ii) o una de sus sales, para el tratamiento de falla cardiaca. | |
CL2008000946A1 (es) | Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun | |
EA201070786A1 (ru) | Бензофуропиримидиноны | |
GT200900283A (es) | "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario". | |
AR058433A1 (es) | Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso | |
DOP2012000149A (es) | Compuestos triciclicos novedosos | |
HRP20120323T1 (en) | Diarylhydantoin compounds | |
CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
ECSP099723A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer | |
AR077629A1 (es) | Mimetico de smac | |
PA8680701A1 (es) | Derivados de oxindol | |
NO20054856D0 (no) | 4-anilo-kinazolinderivater som antiproliferative midler | |
MX2009011579A (es) | Pirimidinonas como moduladores de caseina cinasa ii (ck2). | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2008001705A1 (es) | Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3. | |
UY30846A1 (es) | Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos | |
ATE449776T1 (de) | Pyrroloä2,3-cüpyridinderivate | |
CL2007000595A1 (es) | Compuestos derivados de piperidina; composicion farmaceutica y uso para el tratamiento y/o profilaxis de enfermedades seleccionadas entre hipertension, insuficiencia cardiaca congestiva e insuficiencia renal entre otras. | |
CR20190236A (es) | Compuestos terapéuticos y métodos para utilizarlos | |
AR081819A1 (es) | Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades | |
AR073769A1 (es) | Inhibidores de la integrasa del vih derivados de azepina y oxazepinas condensadas, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de infecciones por vih. | |
PH12019500328A1 (en) | Aza-indazole compounds for use in tendon and/or ligament injuries | |
CL2008001990A1 (es) | Compuestos derivados de amino-quinazolinas sustituidas; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de alzheimer. |